Medicus Pharma Ltd. (MDCX)

Medicus Pharma Ltd. (MDCX) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for unmet medical needs, with corporate offices in Canada and the United States.

Its lead program is SkinJect, a dissolvable microneedle patch loaded with the chemotherapy drug doxorubicin, designed as a non-invasive treatment for basal cell carcinoma of the skin as an alternative to surgical removal. The company has been evaluating the patch in clinical trials in the United States and other countries. Medicus also acquired Antev, a company developing teverelix, a gonadotropin-releasing hormone antagonist being studied for prostate-related conditions, which broadened its pipeline beyond dermatology.